Patent intelligence · US
US 11406616
Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
Patent details — US 11406616
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 9, 2022
- Expiration
- Aug 4, 2042
- Applicant
- SunRegen Healthcare AG
- Claims
- 3
- CPC classes
- A61K, A61K31/215, A61K31/22, A61K31/225
Quick answer
US 11406616 (Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement) is held by SunRegen Healthcare AG. Status: granted. Granted Aug 9, 2022. Expires Aug 4, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SunRegen Healthcare AG
- Grant date
- Expiration
- Claims
- 3
- CPC classes
- A61K, A61K31/215, A61K31/22, A61K31/225, A61K36/11, A61P
More from SunRegen Healthcare AG
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 11406616?
US 11406616 (Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement) is held by SunRegen Healthcare AG. Status: granted. Granted Aug 9, 2022. Expires Aug 4, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11406616?
SunRegen Healthcare AG is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 11406616 expire?
Our index shows an expiration date of Aug 4, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.